CClinicalTrials.gg
No longer availableNCT03265171Updated Apr 24, 2020

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

An expanded access record providing Plasminogen (Human) in Hypoplasminogenemia, sponsored by Prometic Biotherapeutics, Inc.. No longer available. Open to participants aged 16 Months and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Prometic Biotherapeutics, Inc. · Expanded access

Study type
Expanded access
Access type
Individual patients
Ages
16 Months and older
Sex
All
01

Study summary

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

02

Conditions studied

  • Hypoplasminogenemia
03

Who can participate

Ages eligible
16 Months and older
Sexes eligible
All

Inclusion criteria

  • Patient has provided informed consent.
  • Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

Exclusion criteria

Exclusion Criteria:

  • Not applicable
04

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • BiologicalPlasminogen (Human)
05

Where to request access

No study locations are listed for this record.

06

Registry details

Key details

Study ID
NCT03265171
Lead sponsor
Prometic Biotherapeutics, Inc.
Collaborators
Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.
Responsible party
Sponsor
First posted
Aug 29, 2017
Last update
Apr 24, 2020
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion